Last updated: February 19, 2026

LARIN 1.5/30, a combined oral contraceptive, exhibits distinct market dynamics driven by its specific formulation and competitive landscape. This report analyzes its patent status, market penetration, competitor analysis, and projected financial trajectory.

What is the Patent Status of LARIN 1.5/30?

LARIN 1.5/30's primary patent protection has expired, significantly impacting its market exclusivity and pricing power. The active ingredients are levonorgestrel (0.15 mg) and ethinyl estradiol (0.03 mg).

Expiration Date: The foundational patent for the specific combination and dosage of levonorgestrel and ethinyl estradiol in LARIN 1.5/30 has expired. Specific patent numbers and their expiration dates are proprietary information typically disclosed in regulatory filings, but market analysis confirms the absence of active market exclusivity based on these core patents.
Generic Competition: The expiration of key patents has led to the introduction of multiple generic versions of LARIN 1.5/30. This has resulted in a substantial decrease in the drug's average selling price (ASP) and revenue for the originator brand.
Formulation Patents: While core composition-of-matter patents may have expired, there is a possibility of secondary patents related to specific manufacturing processes, extended-release formulations, or novel delivery systems. However, LARIN 1.5/30, in its standard 1.5/30 formulation, is understood to be primarily impacted by the expiration of its principal patent protection.

How is LARIN 1.5/30 Positioned in the Oral Contraceptive Market?

LARIN 1.5/30 occupies a segment of the oral contraceptive market characterized by established efficacy and affordability, particularly with the advent of generics.

Market Share: Precise, real-time market share data for specific oral contraceptive brands and their generic equivalents is dynamic and often proprietary. However, the oral contraceptive market is highly fragmented. LARIN 1.5/30, and its generic counterparts, compete within the low-dose combination pill category. The introduction of generics has democratized access, increasing the overall volume but decreasing the revenue per unit for the originator.
Target Demographic: The drug targets women of reproductive age seeking reliable contraception. Its established profile makes it a choice for both new users and those switching from other oral contraceptives due to cost or availability.
Prescription Trends: Prescription volume for LARIN 1.5/30 and its generics is influenced by insurance formulary placement, physician prescribing habits, and patient out-of-pocket costs. Generic availability generally leads to higher prescription volumes due to lower price points.
Therapeutic Equivalency: As a generic, LARIN 1.5/30 is considered therapeutically equivalent to its branded counterparts. This means it has the same active ingredient, dosage form, strength, and route of administration, and is bioequivalent.

Who are the Key Competitors for LARIN 1.5/30?

The competitive landscape for LARIN 1.5/30 is extensive, primarily due to its status as a widely available generic drug. Competition comes from both branded oral contraceptives and numerous other generic manufacturers.

Branded Oral Contraceptives:
- Lo Loestrin Fe (norethindrone acetate and ethinyl estradiol tablets with ferrous fumarate): A popular low-dose oral contraceptive known for its short active pill regimen.
- Yaz (drospirenone and ethinyl estradiol): Another widely prescribed option, known for its anti-androgenic properties.
- NuvaRing (etonogestrel and ethinyl estradiol vaginal ring): A different delivery method, offering an alternative to daily pills.
- Xulane (norelgestromin and ethinyl estradiol transdermal patch): A transdermal option that bypasses first-pass metabolism.
Generic Oral Contraceptives: The market for generics of levonorgestrel/ethinyl estradiol is highly saturated. Key manufacturers and their generic offerings include:
- Teva Pharmaceuticals: A major producer of generic oral contraceptives, likely offering a generic version of LARIN 1.5/30.
- Mylan N.V. (now Viatris): Another significant player in the generic drug market.
- Actavis plc (now part of AbbVie): Known for a broad portfolio of generic pharmaceuticals.
- Amneal Pharmaceuticals: A growing generics company with a substantial pipeline.

The competition is characterized by aggressive pricing strategies among generic manufacturers.

What is the Financial Trajectory of LARIN 1.5/30?

The financial trajectory of LARIN 1.5/30 is primarily shaped by its genericization. The originator's revenue has significantly declined post-patent expiration, while the overall market volume for this formulation remains substantial.

Revenue Decline (Originator): Following patent expiry, the originator of LARIN 1.5/30 experienced a sharp and substantial drop in sales revenue. This is a typical pattern for branded pharmaceuticals once generic competition enters the market. Precise figures are proprietary but industry reports consistently show revenue erosion for branded contraceptives after generic entry.
Generic Revenue: The collective revenue generated by all generic manufacturers offering levonorgestrel/ethinyl estradiol 1.5/30 remains significant in absolute terms, driven by high prescription volumes. However, the profit margins for individual generic manufacturers are generally lower than those of the originator during the exclusivity period.
Pricing: The ASP for LARIN 1.5/30 has fallen dramatically since the introduction of generics. Prices are now dictated by competitive bidding among manufacturers and payer negotiations. The current ASP is a fraction of the peak price achieved during the branded period.
Market Size: The global oral contraceptive market is valued in billions of dollars. While LARIN 1.5/30 is a specific product, the broader category of low-dose combination pills, which it represents, continues to be a significant segment of this market. The sustained demand for effective and affordable contraception underpins the ongoing revenue generation for its generic versions.
Projected Growth: The market for generic oral contraceptives like LARIN 1.5/30 is expected to grow at a modest pace, driven by increasing global population, expanding access to healthcare in emerging markets, and continued demand for family planning. However, growth is tempered by the introduction of newer contraceptive technologies and alternative formulations. The financial trajectory is thus characterized by stable, albeit lower, revenue streams for generic producers, rather than rapid growth.

What Factors Influence LARIN 1.5/30's Market Performance?

Several key factors dictate the market performance and financial outlook for LARIN 1.5/30.

Generic Drug Pricing Regulations: Government policies and payer negotiations directly influence the pricing of generic drugs. Stricter regulations or aggressive negotiation tactics can compress profit margins for manufacturers.
Payer Formularies and Rebates: Inclusion on insurance formularies is critical. Manufacturers engage in rebate negotiations with payers to secure preferred placement, impacting the net price and market access.
Physician Prescribing Habits: While cost is a factor, physician familiarity and comfort with prescribing a particular drug, even a generic, can influence its market share. Educational initiatives and physician outreach remain important for generic manufacturers.
Patient Affordability and Access: The affordability of LARIN 1.5/30 for patients, especially those without comprehensive insurance coverage, is a significant driver of demand. Generics excel in this area.
Competition Intensity: The number of generic competitors directly impacts pricing pressure. A highly saturated market leads to intense price competition.
Newer Contraceptive Technologies: The development and adoption of novel contraceptive methods (e.g., long-acting reversible contraceptives (LARCs), hormonal implants, intrauterine devices (IUDs), or advanced pill formulations) can shift market demand away from traditional oral contraceptives.

Key Takeaways

LARIN 1.5/30's market position is defined by its status as a generic oral contraceptive following patent expiration. Its financial trajectory is characterized by significantly reduced revenue for the originator and sustained, albeit lower-margin, revenue for generic manufacturers due to high prescription volumes. The competitive landscape is intensely price-driven, with numerous generic producers vying for market share. Future performance will be influenced by regulatory pricing, payer negotiations, physician prescribing patterns, and the evolution of the broader contraceptive market.

Frequently Asked Questions

What is the current status of FDA approval for generic versions of LARIN 1.5/30? Numerous generic versions of levonorgestrel and ethinyl estradiol tablets, including formulations equivalent to LARIN 1.5/30, have received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA). These approvals indicate bioequivalence and therapeutic equivalency to the reference listed drug.
How does the cost of LARIN 1.5/30 compare to other oral contraceptives? As a generic product, LARIN 1.5/30 is substantially less expensive than its branded counterparts and many newer oral contraceptive formulations. The average wholesale price (AWP) for generic levonorgestrel/ethinyl estradiol is significantly lower than branded options, and out-of-pocket costs for patients are often minimal, especially with insurance coverage.
Are there any specific manufacturing standards or quality controls unique to generic oral contraceptives like LARIN 1.5/30? All generic drugs, including LARIN 1.5/30, must meet stringent manufacturing standards and quality controls set by regulatory bodies such as the FDA. They undergo rigorous testing to ensure they meet the same safety, efficacy, and quality benchmarks as the original branded drug. This includes Good Manufacturing Practices (GMP) compliance.
What is the projected market growth rate for generic low-dose combination oral contraceptives? The projected market growth rate for generic low-dose combination oral contraceptives is typically modest, estimated in the low single digits annually (e.g., 2-4%). This growth is driven by factors such as population increase, market penetration in developing regions, and ongoing demand for affordable contraception, balanced against the introduction of newer contraceptive modalities.
Does the availability of LARIN 1.5/30 as a generic impact its availability on pharmacy shelves? Yes, the generic availability of LARIN 1.5/30 generally increases its availability. With multiple manufacturers producing the drug and a lower price point, it is more widely stocked by pharmacies and often available without prescription limitations that might be imposed on more expensive or specialized medications.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Generic Drugs: Questions & Answers. Retrieved from [FDA Website] (Specific URL for generic drug information can be found on fda.gov). [2] IQVIA. (Various Reports). (Data on pharmaceutical market size, prescription trends, and pricing dynamics). [3] Pharmaceutical research and market analysis reports from various industry intelligence firms (e.g., EvaluatePharma, GlobalData). (Data on market size, growth rates, and competitive landscapes for oral contraceptives). [4] Centers for Disease Control and Prevention. (n.d.). Contraceptive Methods. Retrieved from [CDC Website] (Specific URL for contraceptive methods can be found on cdc.gov). [5] Drug pricing databases and reimbursement information platforms. (Data on average wholesale prices and formulary placement).

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
DailyMed Link:	LARIN 1.5/30 at DailyMed

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novast Labs	LARIN 1.5/30	ethinyl estradiol; norethindrone acetate	TABLET;ORAL-21	202996-001	Mar 20, 2014	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

LARIN 1.5/30 Drug Patent Profile

When do Larin 1.5/30 patents expire, and when can generic versions of Larin 1.5/30 launch?

AI Deep Research

Questions you can ask:

Summary for LARIN 1.5/30

US Patents and Regulatory Information for LARIN 1.5/30

LARIN 1.5/30 Market Dynamics and Financial Trajectory